Corlentor

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
12-10-2021
Ciri produk Ciri produk (SPC)
12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
25-02-2019

Bahan aktif:

ivabradine hydrochloride

Boleh didapati daripada:

Les Laboratoires Servier

Kod ATC:

C01EB17

INN (Nama Antarabangsa):

ivabradine

Kumpulan terapeutik:

CARDIAC THERAPY

Kawasan terapeutik:

Angina Pectoris; Heart Failure

Tanda-tanda terapeutik:

Symptomatic treatment of chronic stable angina pectorisIvabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is indicated:in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.Treatment of chronic heart failureIvabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Ringkasan produk:

Revision: 26

Status kebenaran:

Authorised

Tarikh kebenaran:

2005-10-25

Risalah maklumat

                                28
B. PACKAGE LEAFLET
29
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
CORLENTOR 5 MG FILM-COATED TABLETS
CORLENTOR 7.5 MG FILM-COATED TABLETS
ivabradine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Corlentor is and what it is used for
2.
What you need to know before you take Corlentor
3.
How to take Corlentor
4.
Possible side effects
5
How to store Corlentor
6.
Contents of the pack and other information
1.
WHAT CORLENTOR IS AND WHAT IT IS USED FOR
Corlentor (ivabradine) is a heart medicine used to treat:
-
Symptomatic stable angina pectoris (which causes chest pain) in adult
patients whose heart rate is
over or equal to 70 beats per minute.
It is used in adult patients who do not tolerate or cannot take
heart medicines called beta-blockers. It is also used in combination
with beta-blockers in adult
patients whose condition is not fully controlled with a beta-blocker.
-
Chronic heart failure in adult patients whose heart rate is over or
equal to 75 beats per minute. It
is used in combination with standard therapy, including beta-blocker
therapy or when beta-
blockers are contraindicated or not tolerated.
About stable angina pectoris (usually referred to as “angina”):
Stable angina is a heart disease which happens when the heart does not
receive enough oxygen. The
most common symptom of angina is chest pain or discomfort.
About chronic heart failure :
Chronic heart failure is a heart disease which happens when your heart
cannot pump enough blood to
the rest of your body. The most common s
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Corlentor 5 mg film-coated tablets
Corlentor 7.5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Corlentor 5 mg film-coated tablets
Each film-coated tablet contains 5 mg ivabradine (as hydrochloride).
_Excipient with known effect:_
Each film-coated tablet contains 63.91 mg lactose monohydrate.
Corlentor 7.5 mg film-coated tablets
Each film-coated tablet contains 7.5 mg ivabradine (as hydrochloride).
_Excipient with known effect:_
Each film-coated tablet contains 61.215 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Corlentor 5 mg film-coated tablets
Salmon-coloured, oblong, film-coated tablet scored on both sides,
engraved with “5” on one face
and
on the other face.
The tablet can be divided into equal doses.
Corlentor 7.5 mg film-coated tablets
Salmon-coloured, triangular, film-coated tablet engraved with
“7.5” on one face and
on the other
face.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Symptomatic treatment of chronic stable angina pectoris
Ivabradine is indicated for the symptomatic treatment of chronic
stable angina pectoris in coronary
artery disease adults with normal sinus rhythm and heart rate ≥ 70
bpm. Ivabradine is indicated :
-
in adults unable to tolerate or with a contraindication to the use of
beta-blockers
-
or in combination with beta-blockers in patients inadequately
controlled with an optimal beta-
blocker dose.
Treatment of chronic heart failure
3
Ivabradine is indicated in chronic heart failure NYHA II to IV class
with systolic dysfunction, in adult
patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in
combination with standard therapy
including beta-blocker therapy or when beta-blocker therapy is
contraindicated or not tolerated (see
section 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Symptomatic treatment of chronic stable angina pectoris _
It is recommended that the decision to ini
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 12-10-2021
Ciri produk Ciri produk Bulgaria 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 25-02-2019
Risalah maklumat Risalah maklumat Sepanyol 12-10-2021
Ciri produk Ciri produk Sepanyol 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 25-02-2019
Risalah maklumat Risalah maklumat Czech 12-10-2021
Ciri produk Ciri produk Czech 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Czech 25-02-2019
Risalah maklumat Risalah maklumat Denmark 12-10-2021
Ciri produk Ciri produk Denmark 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 25-02-2019
Risalah maklumat Risalah maklumat Jerman 12-10-2021
Ciri produk Ciri produk Jerman 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 25-02-2019
Risalah maklumat Risalah maklumat Estonia 12-10-2021
Ciri produk Ciri produk Estonia 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 25-02-2019
Risalah maklumat Risalah maklumat Greek 12-10-2021
Ciri produk Ciri produk Greek 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Greek 25-02-2019
Risalah maklumat Risalah maklumat Perancis 12-10-2021
Ciri produk Ciri produk Perancis 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 25-02-2019
Risalah maklumat Risalah maklumat Itali 12-10-2021
Ciri produk Ciri produk Itali 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Itali 25-02-2019
Risalah maklumat Risalah maklumat Latvia 12-10-2021
Ciri produk Ciri produk Latvia 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 25-02-2019
Risalah maklumat Risalah maklumat Lithuania 12-10-2021
Ciri produk Ciri produk Lithuania 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 25-02-2019
Risalah maklumat Risalah maklumat Hungary 12-10-2021
Ciri produk Ciri produk Hungary 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 25-02-2019
Risalah maklumat Risalah maklumat Malta 12-10-2021
Ciri produk Ciri produk Malta 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Malta 25-02-2019
Risalah maklumat Risalah maklumat Belanda 12-10-2021
Ciri produk Ciri produk Belanda 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 25-02-2019
Risalah maklumat Risalah maklumat Poland 12-10-2021
Ciri produk Ciri produk Poland 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Poland 25-02-2019
Risalah maklumat Risalah maklumat Portugis 12-10-2021
Ciri produk Ciri produk Portugis 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 25-02-2019
Risalah maklumat Risalah maklumat Romania 12-10-2021
Ciri produk Ciri produk Romania 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Romania 25-02-2019
Risalah maklumat Risalah maklumat Slovak 12-10-2021
Ciri produk Ciri produk Slovak 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 25-02-2019
Risalah maklumat Risalah maklumat Slovenia 12-10-2021
Ciri produk Ciri produk Slovenia 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 25-02-2019
Risalah maklumat Risalah maklumat Finland 12-10-2021
Ciri produk Ciri produk Finland 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Finland 25-02-2019
Risalah maklumat Risalah maklumat Sweden 12-10-2021
Ciri produk Ciri produk Sweden 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 25-02-2019
Risalah maklumat Risalah maklumat Norway 12-10-2021
Ciri produk Ciri produk Norway 12-10-2021
Risalah maklumat Risalah maklumat Iceland 12-10-2021
Ciri produk Ciri produk Iceland 12-10-2021
Risalah maklumat Risalah maklumat Croat 12-10-2021
Ciri produk Ciri produk Croat 12-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Croat 25-02-2019

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen